Gilead Sciences is undervalued, with a Buy rating and a DCF-based target price of $141, implying 13.4% upside. Click here to ...

Gilead Sciences (GILD) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to ...

Gilead's Q3 results exceeded expectations, with EPS of $2.47 and revenue of $7.8 billion, driven by HIV franchise ...

Gilead Sciences, Inc. (NASDAQ:GILD) ranks among the best slow growth stocks to invest in. On November 21, Mizuho increased its price target for Gilead Sciences, Inc. (NASDAQ:GILD) from $131 to $140 ...

Context for Gilead Sciences stock today Gilead Sciences (GILD) is in focus for investors after recent share price moves, with ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for ...

Gilead Sciences is expected to release its fiscal fourth-quarter earnings soon, and analysts project a decline in EPS.

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common ...

Investors in Gilead Sciences Inc (Symbol: GILD) saw new options become available today, for the January 2026 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ...

Shares of Gilead Sciences, Inc. (GILD) gained 7.3% after the company reported solid results for the second quarter of 2025 and raised its annual guidance for 2025. Concurrently, GILD raised full-year ...